SK390491A3 - 1H-IMIDAZO/4,5-C/QUINOLIN-4-AMINE DERIVATIVES AND ANTIVIRALì (54) PHARMACEUTICAL COMPOSITIONS BASED THEREUPON - Google Patents

1H-IMIDAZO/4,5-C/QUINOLIN-4-AMINE DERIVATIVES AND ANTIVIRALì (54) PHARMACEUTICAL COMPOSITIONS BASED THEREUPON Download PDF

Info

Publication number
SK390491A3
SK390491A3 SK3904-91A SK390491A SK390491A3 SK 390491 A3 SK390491 A3 SK 390491A3 SK 390491 A SK390491 A SK 390491A SK 390491 A3 SK390491 A3 SK 390491A3
Authority
SK
Slovakia
Prior art keywords
imidazo
quinolin
amine
quinoline
carbon atoms
Prior art date
Application number
SK3904-91A
Other languages
English (en)
Slovak (sk)
Inventor
John F Gerster
Original Assignee
Riker Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riker Laboratories Inc filed Critical Riker Laboratories Inc
Publication of SK390491A3 publication Critical patent/SK390491A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK3904-91A 1983-11-18 1991-12-19 1H-IMIDAZO/4,5-C/QUINOLIN-4-AMINE DERIVATIVES AND ANTIVIRALì (54) PHARMACEUTICAL COMPOSITIONS BASED THEREUPON SK390491A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55315883A 1983-11-18 1983-11-18
US06/798,385 US4689338A (en) 1983-11-18 1985-11-15 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use

Publications (1)

Publication Number Publication Date
SK390491A3 true SK390491A3 (en) 2000-09-12

Family

ID=24208340

Family Applications (1)

Application Number Title Priority Date Filing Date
SK3904-91A SK390491A3 (en) 1983-11-18 1991-12-19 1H-IMIDAZO/4,5-C/QUINOLIN-4-AMINE DERIVATIVES AND ANTIVIRALì (54) PHARMACEUTICAL COMPOSITIONS BASED THEREUPON

Country Status (6)

Country Link
US (1) US4689338A (pt)
BR (1) BR1100396A (pt)
CZ (1) CZ390491A3 (pt)
IL (1) IL73534A (pt)
MX (1) MX9203474A (pt)
SK (1) SK390491A3 (pt)

Families Citing this family (441)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335996C (en) * 1988-02-16 1995-06-20 Susumu Takada 2-substituted carbonylimidazo¬4,5-c|quinolines
IL92537A (en) * 1988-12-15 1994-04-12 Riker Laboratories Inc Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5736553A (en) * 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US5756747A (en) * 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US4994468A (en) * 1989-03-07 1991-02-19 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinolone derivatives
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) * 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
GB8928281D0 (en) * 1989-12-14 1990-02-21 Smith Kline French Lab Compounds
EP0459505B1 (en) * 1990-06-01 1996-10-02 Kyowa Hakko Kogyo Co., Ltd. Imidazonaphthyridine derivatives
DK0553202T3 (da) * 1990-10-05 1995-07-03 Minnesota Mining & Mfg Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
WO1992015582A1 (en) * 1991-03-01 1992-09-17 Minnesota Mining And Manufacturing Company 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6608201B2 (en) * 1992-08-28 2003-08-19 3M Innovative Properties Company Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
KR100341341B1 (ko) * 1993-07-15 2002-11-25 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 이미다조[4,5-c]피리딘-4-아민
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5644063A (en) * 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
HUP9904665A3 (en) 1996-10-25 2000-11-28 Minnesota Mining And Mfg Co Sa Immune response modifier compounds for treatment of th2 mediated and related diseases
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4101302B2 (ja) * 1997-01-09 2008-06-18 テルモ株式会社 新規アミド誘導体および合成中間体
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
AU2002300985B2 (en) * 1997-12-11 2004-12-02 Minnesota Mining And Manufacturing Company Imidazonaphthyridines And Their Use In Inducing Cytokine Biosynthesis
SI1040112T1 (en) * 1997-12-11 2005-02-28 Minnesota Mining And Manufacturing Company Imidazonaphthyridines and their use in inducing cytokine biosynthesis
US6312715B1 (en) 1998-05-01 2001-11-06 3M Innovative Properties Company Adhesive microsphere drug delivery composition
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US6518280B2 (en) * 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
BR0007435A (pt) * 1999-01-08 2001-12-04 3M Innovative Properties Co Formulações e métodos para tratamento decondições associadas com mucosa com ummodificador de resposta imunológica
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6376669B1 (en) * 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
GB0023008D0 (en) * 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
AU2002232498B2 (en) * 2000-12-08 2006-05-04 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
CA2598144A1 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
UA74593C2 (en) * 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
DE60228229D1 (de) * 2001-04-17 2008-09-25 Dainippon Sumitomo Pharma Co Neue adeninderivate
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
US6893655B2 (en) 2001-10-09 2005-05-17 3M Innovative Properties Co. Transdermal delivery devices
WO2003094836A2 (en) * 2001-10-12 2003-11-20 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
EP1455700A4 (en) * 2001-11-16 2007-02-14 3M Innovative Properties Co METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS
NZ532769A (en) * 2001-11-29 2005-12-23 3M Innovative Properties Co Pharmaceutical formulations comprising an immune response modifier
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2003072026A2 (en) * 2002-02-22 2003-09-04 3M Innovative Properties Company Method of reducing and treating uvb-induced immunosuppression
EP1487486B1 (en) * 2002-03-19 2009-01-14 PowderJect Research Limited Imidazoquinolineamines as adjuvants in hiv dna vaccination
EP1487485B1 (en) * 2002-03-19 2010-12-15 PowderJect Research Limited Imidazoquinoline adjuvants for dna vaccines
EP2368431A1 (en) 2002-04-04 2011-09-28 Coley Pharmaceutical GmbH Immunostimulatory G,U-containing oligoribonucleotides
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
EP1511746A2 (en) 2002-05-29 2005-03-09 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
EP1513524A4 (en) * 2002-06-07 2008-09-03 3M Innovative Properties Co WITH ETHER SUBSTITUTED IMIDAZOPYRIDINE
MXPA05000893A (es) 2002-07-23 2005-09-30 Biogal Gyogyszergyar Preparacion de 1h-imidazo[4,5-c]quinolin-4-aminas a traves de compuestos intermedios 1h-imidazo [4,5-c] quinolin-4-ftalimida.
SI1539752T1 (sl) * 2002-07-26 2007-08-31 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Priprava 1H-imidazo(4,5-c)kinolin-4-aminov preko novih imidazo(4,5-c)kinolin-4-ciano in 1H-imidazo(4,5-c)kinolin-4- karboksamidnih intermediatov
DK1545597T3 (da) 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
JP2006503068A (ja) * 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー １ｈ−イミダゾダイマー
MXPA05003193A (es) * 2002-09-27 2005-06-08 Sumitomo Pharma Compuesto de adenina novedoso y uso del mismo.
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003301052A1 (en) 2002-12-20 2004-07-22 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
AU2003300184B8 (en) 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
JP2006519020A (ja) * 2003-02-27 2006-08-24 スリーエム イノベイティブ プロパティズ カンパニー Ｔｌｒ介在生物活性の選択的調節
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
KR20050107497A (ko) * 2003-03-07 2005-11-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 1-아미노 1ｈ-이미다조퀴놀린
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
EP1603476A4 (en) * 2003-03-13 2010-01-13 3M Innovative Properties Co PROCESS FOR REMOVING TATTOO
WO2004080293A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
KR20050109562A (ko) * 2003-03-13 2005-11-21 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피부의 질을 개선시키는 방법
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US7923560B2 (en) * 2003-04-10 2011-04-12 3M Innovative Properties Company Delivery of immune response modifier compounds
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US6943255B2 (en) * 2003-06-06 2005-09-13 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
US20050032829A1 (en) * 2003-06-06 2005-02-10 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
US7521459B2 (en) * 2003-07-28 2009-04-21 Metabeauty Inc. Method for treating damaged skin
MXPA06001004A (es) * 2003-07-31 2006-04-27 3M Innovative Properties Co Composiciones para encapsulacion y liberacion controlada.
WO2005016275A2 (en) * 2003-08-05 2005-02-24 3M Innovative Properties Company Formulations containing an immune response modifier
US8211906B1 (en) 2003-08-05 2012-07-03 Scherrer Lawrence C Method of inhibiting growth of neoplastic cells and inhibiting infection by administering an immune enhancer drug
MXPA06001674A (es) 2003-08-12 2006-05-12 3M Innovative Properties Co Compuestos que contienen imidazo hidroxilamina-sustituidos.
AU2004266657B2 (en) 2003-08-14 2009-07-02 3M Innovative Properties Company Lipid-modified immune response modifiers
JP2007503268A (ja) * 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
EP1660122A4 (en) * 2003-08-25 2007-10-24 3M Innovative Properties Co IMMUNOSTIMULATORY COMBINATIONS AND TREATMENTS
EP1658076B1 (en) 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504172A (ja) * 2003-09-02 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 粘膜に関連した症状の処置に関する方法
EP1660026A4 (en) 2003-09-05 2008-07-16 3M Innovative Properties Co TREATMENT FOR CD5 + B CELL LYMPHOMA
JP2007505629A (ja) * 2003-09-17 2007-03-15 スリーエム イノベイティブ プロパティズ カンパニー Ｔｌｒ遺伝子発現の選択的調節
WO2005033049A2 (en) * 2003-10-01 2005-04-14 Taro Pharmaceuticals U.S.A., Inc. METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF
AU2004278014B2 (en) 2003-10-03 2011-04-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
CA2540598C (en) 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
AU2004285575A1 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
EP1687022A4 (en) 2003-11-12 2008-02-13 Medical Res Council RENTA: HIV IMMUNOGEN, AND USES OF RENTA
EP1685129A4 (en) 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
CN1906192A (zh) 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
AR046781A1 (es) 2003-11-25 2005-12-21 3M Innovative Properties Co Derivados de imidazoquinolinas. composiciones farmaceuticas.
CA2547085A1 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2005055932A2 (en) * 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
CN1914203A (zh) * 2003-12-04 2007-02-14 3M创新有限公司 砜取代的咪唑环醚
WO2005066172A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US20050239735A1 (en) * 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
CA2551399A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
US20050201959A1 (en) * 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
CA2559607C (en) * 2004-03-15 2013-02-19 3M Innovative Properties Company Immune response modifier formulations and methods
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
BRPI0509258A8 (pt) 2004-03-26 2019-01-22 Astrazeneca Ab composto de 8-oxoadenina 9-substituída
US20070225303A1 (en) * 2004-03-26 2007-09-27 Haruhisa Ogita 8-Oxoadenine Compound
US20070166384A1 (en) * 2004-04-09 2007-07-19 Zarraga Isidro Angelo E Methods , composition and preparations for delivery of immune response modifiers
CA2564855A1 (en) * 2004-04-28 2005-10-28 3M Innovative Properties Company Compositions and methods for mucosal vaccination
EP1766034B1 (en) 2004-05-21 2014-03-19 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7884207B2 (en) * 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
ITMI20041282A1 (it) * 2004-06-24 2004-09-24 Dipharma Spa Procedimento per la preparazione di imiquimod
US20060045886A1 (en) * 2004-08-27 2006-03-02 Kedl Ross M HIV immunostimulatory compositions
PL1789042T3 (pl) * 2004-09-02 2012-09-28 3M Innovative Properties Co Układy pierścieni 1-alkoksy 1H-imidazo i sposoby
WO2006029115A2 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
WO2006031878A2 (en) * 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
WO2006042254A2 (en) * 2004-10-08 2006-04-20 3M Innovative Properties Company Adjuvant for dna vaccines
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
EP1831214A1 (en) * 2004-12-27 2007-09-12 Usv Limited A process for preparation of 4-amino-1-isobutyl-1h-imidazo[4,5-c]-quinoline (imiquimod)
AU2005322898B2 (en) 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
EP1831221B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Substituted chiral fused 1,2 imidazo 4,5-c ring compounds
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
JP2008526765A (ja) 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 皮膚転移の処置
JP2008526751A (ja) * 2004-12-30 2008-07-24 武田薬品工業株式会社 １−（２−メチルプロピル）−１ｈ−イミダゾ［４，５−ｃ］［１，５］ナフチリジン−４−アミンエタンスルホナート及び１−（２−メチルプロピル）−１ｈ−イミダゾ［４，５−ｃ］［１，５］ナフチリジン−４−アミンメタンスルホナート
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
CA2597324C (en) 2005-02-09 2015-06-30 Coley Pharmaceutical Group, Inc. Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
EP1877056A2 (en) 2005-02-09 2008-01-16 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazoloý4,5-c¨ring compounds and methods
CA2597446A1 (en) * 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
MX291624B (es) 2005-02-18 2011-11-04 Novartis Vaccines & Diagnostic Inmunogenos de escherichia coli uropatogenica.
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
WO2006091647A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
WO2006091567A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
EP1851220A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
US8178677B2 (en) 2005-02-23 2012-05-15 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
JP2008533148A (ja) * 2005-03-14 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー 光線性角化症の治療方法
AU2006226412A1 (en) * 2005-03-21 2006-09-28 Ferrer Internacional, S. A. Method for making 1-substituted 1H-imidazo(4,5-c)quinolin-4-amine compounds and intermediates therefor
JP2008535832A (ja) 2005-04-01 2008-09-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ピラゾロピリジン−１，４−ジアミン、およびそのアナログ
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
AU2006241166A1 (en) * 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
CA2615626A1 (en) 2005-07-18 2007-01-25 Novartis Ag Small animal model for hcv replication
JP2009504803A (ja) 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒアゴニスト
JP2009507856A (ja) 2005-09-09 2009-02-26 コーリー ファーマシューティカル グループ，インコーポレイテッド Ｎ−｛２−［４−アミノ−２−（エトキシメチル）−１Ｈ−イミダゾ［４，５−ｃ］キノリン−１−イル］−１，１−ジメチルエチル｝メタンスルホンアミドのアミドおよびカルバマート誘導体ならびに方法
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
WO2007034916A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
TW200745114A (en) * 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
WO2007034882A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
JPWO2007034817A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
US20090105212A1 (en) 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
US20090192153A1 (en) * 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
US20070081962A1 (en) * 2005-10-06 2007-04-12 Amit Munshi Novel delivery of immune response modifiers for removal of chronic tattoos
US7629027B2 (en) * 2005-10-14 2009-12-08 3M Innovative Properties Company Method for making chromonic nanoparticles
US7718716B2 (en) * 2005-10-14 2010-05-18 3M Innovative Properties Company Chromonic nanoparticles containing bioactive compounds
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
US20070100146A1 (en) * 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
AU2006311871B2 (en) 2005-11-04 2011-03-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
PT2368572T (pt) 2005-11-04 2020-06-16 Seqirus Uk Ltd Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
US20070128291A1 (en) * 2005-12-07 2007-06-07 Tokie Jeffrey H Method and Apparatus for Forming Chromonic Nanoparticles
US7807661B2 (en) * 2005-12-08 2010-10-05 3M Innovative Properties Company Silver ion releasing articles and methods of manufacture
US7323568B2 (en) * 2005-12-12 2008-01-29 Chemagis Ltd. Process for preparing Imiquimod
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR20080089663A (ko) 2006-01-27 2008-10-07 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US8951528B2 (en) 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
US8088788B2 (en) 2006-03-15 2012-01-03 3M Innovative Properties Company Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods
ATE539079T1 (de) * 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
CA2646891A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
AU2007231027B2 (en) 2006-03-24 2013-10-03 Novartis Influenza Vaccines Marburg Gmbh Storage of influenza vaccines without refrigeration
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US20090186047A1 (en) * 2006-04-25 2009-07-23 Intercell Ag HCV Vaccinations
US20070275185A1 (en) * 2006-05-23 2007-11-29 3M Innovative Properties Company Method of making ordered nanostructured layers
WO2007142755A2 (en) 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
AU2007256717B2 (en) 2006-06-02 2013-06-20 International Aids Vaccine Initiative HIV-1 Clade A consensus sequences, antigens, and transgenes
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
CN101472610A (zh) 2006-06-20 2009-07-01 特朗斯吉有限公司 重组病毒疫苗
US8138172B2 (en) * 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) * 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
EP2046121B1 (en) 2006-07-14 2012-08-22 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
US20100092401A1 (en) * 2006-07-18 2010-04-15 Graceway Pharmaceuticals, Llc Immune response modifier formulations
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008016475A2 (en) * 2006-07-31 2008-02-07 3M Innovative Properties Company Immune response modifier compositions and methods
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
WO2008023333A2 (en) * 2006-08-22 2008-02-28 Ranbaxy Laboratories Limited Process for the preparation of 4-(isobutylamino)-3-amino-quinoline
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
AU2007297178B2 (en) 2006-09-11 2014-07-24 Novartis Ag Making influenza virus vaccines without using eggs
US20080103310A1 (en) * 2006-10-16 2008-05-01 Janos Hajko Preparation of 1H-imidazo[4,5-c]quinolin-4-amines via 1H-imidazo[4, 5-c]quinolin-4-phtalimide intermediates
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US7943771B2 (en) * 2007-01-24 2011-05-17 Chemagis Ltd. Imiquimod production process
PL2115140T3 (pl) 2007-01-31 2017-03-31 Yu Dodatnio naładowane rozpuszczalne w wodzie proleki 1H-imidazo[4,5-c]chinolino-4-amin i powiązane związki o bardzo wysokich wskaźnikach penetracji przez skórę
CN106432226B (zh) * 2007-01-31 2019-08-30 于崇曦 1H-咪唑并[4,5-c]喹啉-4-胺类及其相关化合物的前药
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
US7659398B2 (en) * 2007-02-14 2010-02-09 Chemagis Ltd. Imiquimod production process
EP1958613A1 (en) * 2007-02-15 2008-08-20 Polichem S.A. Dermal film-forming liquid formulations for drug release to skin
ES2457316T3 (es) * 2007-03-19 2014-04-25 Astrazeneca Ab Compuestos 8-oxo-adenina 9 sustituidos como moduladores del receptor similares a toll (TLR7)
EP2139894B1 (en) * 2007-03-19 2011-10-26 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
WO2008114819A1 (ja) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
PE20081887A1 (es) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
WO2008118763A1 (en) * 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc. Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008118881A1 (en) * 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Method and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008118765A1 (en) * 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
MY150519A (en) * 2007-05-08 2014-01-30 Astrazeneca Ab Imidazoquinolines with immuno-modulating properties
US9371284B2 (en) 2007-06-04 2016-06-21 Techfields Pharma Co., Ltd. Pro-drugs of NSAIAS with very high skin and membranes penetration rates and their new medicinal uses
NZ582595A (en) 2007-06-27 2012-07-27 Novartis Ag Low-additive influenza vaccines
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
MX2010002773A (es) 2007-09-12 2010-03-31 Novartis Ag Antigenos mutantes de gas57 y anticuerpos de gas57.
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
UY31531A1 (es) 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PA8809001A1 (es) 2007-12-20 2009-07-23 Novartis Ag Compuestos organicos
JP5656642B2 (ja) 2007-12-21 2015-01-21 ノバルティス アーゲー ストレプトリシンｏの変異体形態
BRPI0907191A2 (pt) * 2008-01-15 2015-07-14 Dow Pharmaceutical Sciences Solução, método para preparar uma solução, método para aumentar a penetração cutânea de imiquimod ou um análogo do mesmo
WO2009099650A2 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
PT2268618E (pt) * 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
NZ587798A (en) 2008-03-18 2013-06-28 Novartis Ag Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
KR20230085223A (ko) 2008-12-04 2023-06-13 충시 위 고투과력을 가진 조성물 및 이의 적용
AU2009335943A1 (en) * 2008-12-19 2013-10-24 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
CN102481349B (zh) 2009-01-12 2014-10-15 诺华股份有限公司 抗革兰氏阳性细菌疫苗中的Cna_B结构域
NZ593749A (en) 2009-01-20 2012-05-25 Transgene Sa Soluble icam-1 as biomarker for prediction of therapeutic response
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
BRPI1008383A2 (pt) * 2009-02-11 2016-02-23 Univ California composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
US20120028279A1 (en) 2009-03-24 2012-02-02 Bruce Acres Biomarker for monitoring patients
MX2011010050A (es) 2009-03-25 2011-12-14 Univ Texas Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
JP5830009B2 (ja) 2009-04-14 2015-12-09 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対して免疫化するための組成物
BRPI1010512A2 (pt) 2009-04-17 2016-03-15 Transgène S A "método ex vivo para avaliar a eficácia de um tratamento envolvendo a administração de uma composição imunogênica a um paciente, e, uso de níveis de linfócitos t ativados (cd3 + cd69+) como um biomarcador"
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
EA201101650A1 (ru) 2009-05-21 2012-07-30 Астразенека Аб Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
DK2452194T3 (en) 2009-07-10 2015-11-30 Transgene Sa Biomarker PATIENT SELECTION AND RELATED PRACTICES
AU2010274097B2 (en) 2009-07-13 2016-06-16 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US20120164176A1 (en) 2009-07-15 2012-06-28 Kurt Swanson Rsv f protein compositions amd methods for making same
SG178035A1 (en) 2009-07-16 2012-03-29 Novartis Ag Detoxified escherichia coli immunogens
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
SG170622A1 (en) 2009-10-09 2011-05-30 Nitto Denko Corp A passive drug delivery device and a method of drug delivery
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2507237A1 (en) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
EP2558069A1 (en) 2010-04-13 2013-02-20 Novartis AG Benzonapthyridine compositions and uses thereof
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
EA201291442A1 (ru) 2010-06-25 2013-04-30 Медисиз Фармасьютикал Корпорейшн Комбинированная терапия с криохирургией и имиквимодом с низкой дозировкой для лечения актинического кератоза
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
US9072876B2 (en) 2010-08-05 2015-07-07 Medicis Pharmaceutical Corporation Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
CN105294684B (zh) 2010-08-17 2018-04-06 3M创新有限公司 脂质化免疫反应调节剂化合物的组合物、制剂及方法
EP2651937B8 (en) 2010-12-16 2016-07-13 Sumitomo Dainippon Pharma Co., Ltd. Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
WO2012080730A1 (en) 2010-12-17 2012-06-21 Astrazeneca Ab Purine derivatives
ES2727836T3 (es) 2011-01-26 2019-10-21 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
PE20140293A1 (es) 2011-01-31 2014-03-19 Novartis Ag Novedosos derivados heterociclicos
AP2013007180A0 (en) 2011-04-25 2013-10-31 Advanced Bioscience Lab Inc Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
CA2838158C (en) 2011-06-03 2019-07-16 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EP3153180A1 (en) 2011-06-03 2017-04-12 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9492682B2 (en) 2011-09-14 2016-11-15 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
WO2013041247A1 (en) 2011-09-23 2013-03-28 Westfällsche Wilhelms-Universitaet Muenster Yersinia outer protein m (yopm) in the treatment of psoriasis induced by imiquimod
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2771342B1 (en) 2011-10-28 2016-05-18 Novartis AG Purine derivatives and their use in the treatment of disease
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
WO2013162828A1 (en) 2012-04-27 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing
RU2737765C2 (ru) 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
AU2013263043B2 (en) 2012-05-16 2016-06-16 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
CA2871589C (en) 2012-05-18 2020-12-22 Seiji Hori Pyrimidine carboxylic acid derivatives and their use as tlr7 agonists
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
JP6189948B2 (ja) 2012-06-29 2017-08-30 ファイザー・インク ＬＲＲＫ２阻害薬としての新規な４−（置換アミノ）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン
CN104853770A (zh) 2012-07-06 2015-08-19 诺华股份有限公司 免疫原性组合物及其应用
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
ES2807173T3 (es) 2012-09-10 2021-02-22 Int Aids Vaccine Initiative Inmunógenos de anticuerpos ampliamente neutralizantes del VIH-1, métodos de generación y usos de los mismos
EP2897548A4 (en) 2012-09-21 2016-05-25 3M Innovative Properties Co INCISION PROTECTION
CA2889903C (en) 2012-10-29 2021-03-09 Manjinder Singh Phull Antiviral phosphonate analogues and process for preparation thereof
EP2730271B1 (en) 2012-11-11 2018-01-24 Symrise AG Aqeuous compositions
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
WO2014107663A2 (en) 2013-01-07 2014-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US9295732B2 (en) 2013-02-22 2016-03-29 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
ES2701758T3 (es) 2013-02-27 2019-02-25 Symrise Ag Extracto de jengibre para la protección de citoblastos
CA2904507C (en) 2013-03-10 2021-05-04 Peritech Pharma Ltd. Topical compositions and methods of treatment of topical disorders
WO2014201245A1 (en) 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
US9919029B2 (en) 2013-07-26 2018-03-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP2862852B1 (en) 2013-10-18 2018-07-04 Symrise AG Urea derivatives for the protection of stem cells
US11020486B2 (en) 2013-11-05 2021-06-01 3M Innovative Properties Company Sesame oil based injection formulations
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
TN2016000179A1 (en) 2013-12-06 2017-10-06 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
US10548985B2 (en) 2014-01-10 2020-02-04 Birdie Biopharmaceuticals, Inc. Compounds and compositions for treating EGFR expressing tumors
EP3094342A4 (en) 2014-01-15 2017-12-27 Nikolai Khodarev Anti-tumor therapy
EP2921157B1 (en) 2014-03-18 2017-08-16 Symrise AG Coated titanium dioxide to reduce whitening effect on skin
MX2016012538A (es) 2014-03-26 2016-12-14 Glaxosmithkline Biologicals Sa Antigenos estafilococicos mutantes.
ES2819207T3 (es) 2014-04-29 2021-04-15 Symrise Ag Mezclas activas
WO2015171975A1 (en) 2014-05-09 2015-11-12 The Regents Of The University Of Michigan Use of modified banana lectin in purification of glycoproteins
US10093720B2 (en) 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
EP3166976B1 (en) 2014-07-09 2022-02-23 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
FR3031105B1 (fr) 2014-12-31 2018-04-06 Universite De Montpellier Nouveaux imidazo[1,2-a]quinoxalines et derives pour le traitement des cancers
EP3045161A1 (en) 2015-01-18 2016-07-20 Symrise AG Active compositions comprising 1,2-hexanediol and 1,2-octanediol
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2016183371A1 (en) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for the treatment or prevention of ischemic tissue damage
EP3344622B1 (en) 2015-08-31 2021-07-07 3M Innovative Properties Company Guanidine substituted, fused 1h-imidazo[4,5-c]pyridine compounds useful in the treatment of viral and neoplastic diseases
JP6956071B2 (ja) 2015-08-31 2021-10-27 スリーエム イノベイティブ プロパティズ カンパニー 置換グアニジン基を含有するイミダゾ［４，５−ｃ］環状化合物
WO2017044803A1 (en) 2015-09-09 2017-03-16 The United States Of America, As Represented By The Secretary Department Of Health And Human Service Expression vector delivery system and use thereof for inducing an immune response
WO2017046675A1 (en) * 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
WO2017056494A1 (en) 2015-09-29 2017-04-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
TWI718188B (zh) 2015-10-07 2021-02-11 日商大日本住友製藥股份有限公司 嘧啶化合物
RU2018119085A (ru) 2015-11-02 2019-12-04 Новартис Аг Схема введения ингибитора фосфатидилинозитол-3-киназы
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
WO2017147597A1 (en) 2016-02-27 2017-08-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide vaccines comprising self-assembling polymer nanoparticles
US10533007B2 (en) * 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
CA3023672A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
US11344619B2 (en) 2016-05-16 2022-05-31 Access To Advanced Health Institute Formulation containing TLR agonist and methods of use
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
US10414779B2 (en) 2016-08-26 2019-09-17 3M Innovative Properties Company Fused [1,2]imidazo[4,5-C] ring compounds substituted with guanidino groups
JP7240311B2 (ja) 2016-08-30 2023-03-15 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド 薬物送達組成物およびその使用
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US10941252B2 (en) 2016-11-03 2021-03-09 3M Innovative Properties Company Silicone copolymers, methods of making, and articles
CN110234401B (zh) 2016-11-09 2024-03-01 德克萨斯大学系统董事会 用于适应性免疫调节的方法和组合物
CA3045517A1 (en) 2016-12-05 2018-06-14 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
WO2018160552A1 (en) 2017-03-01 2018-09-07 3M Innovative Properties Company IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS
MX2019010756A (es) * 2017-03-10 2020-01-20 Pfizer Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
EP3603619A4 (en) 2017-03-29 2020-12-09 Sumitomo Dainippon Pharma Co., Ltd. VACCINAL ADJUVANT FORMULATION
AU2018250226A1 (en) 2017-04-04 2019-10-10 Barinthus Biotherapeutics North America, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
EP3625231B1 (en) * 2017-05-19 2022-07-20 Superb Wisdom Limited Derivatives of resiquimod
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
US11517567B2 (en) * 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
US10618896B2 (en) 2017-08-22 2020-04-14 Dynavax Technologies Corporation Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
EP3710059A1 (en) 2017-11-14 2020-09-23 Dynavax Technologies Corporation Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
EP3728255B1 (en) 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
CN116115765A (zh) 2017-12-21 2023-05-16 住友制药株式会社 包含tlr7激动剂的组合药物
AU2019228381B2 (en) 2018-02-28 2021-12-16 Pfizer Inc. IL-15 variants and uses thereof
CN111788202B (zh) 2018-02-28 2024-03-01 3M创新有限公司 具有N-1支链基团的经取代的咪唑并[4,5-c]喹啉化合物
WO2019226828A2 (en) 2018-05-22 2019-11-28 Avidea Technologies, Inc. Improved methods of manufacturing peptide-based vaccines
TWI803637B (zh) 2018-05-23 2023-06-01 美商輝瑞大藥廠 特異性針對gucy2c之抗體及其用途
PE20210127A1 (es) 2018-05-23 2021-01-19 Pfizer Anticuerpos especificos para cd3 y sus usos
JP7394790B2 (ja) 2018-05-24 2023-12-08 スリーエム イノベイティブ プロパティズ カンパニー Ｎ－１分枝状シクロアルキル置換イミダゾ［４，５－ｃ］キノリン化合物、組成物、及び方法
AU2019277361A1 (en) 2018-05-30 2020-12-17 Translate Bio, Inc. Messenger RNA vaccines and uses thereof
AR114910A1 (es) 2018-06-04 2020-10-28 Apros Therapeutics Inc Compuestos de pirimidina que contienen grupos ácidos
TW202011986A (zh) 2018-07-23 2020-04-01 公益財團法人日本健康科學振興財團 包含流感疫苗之組合物
WO2020061564A1 (en) 2018-09-23 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
US20210393523A1 (en) 2018-10-03 2021-12-23 Avldea Technologies, Inc. Aromatic ring substituted amphiphilic polymers as drug delivery systems
CN113166143B (zh) 2018-11-26 2024-06-04 舒万诺知识产权公司 N-1支链烷基醚取代的咪唑并[4,5-c]喹啉化合物、组合物和方法
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20230026627A1 (en) 2019-04-17 2023-01-26 Vaccitech North America, Inc. Compositions and Methods of Manufacturing Star Polymers for Ligand Display and/or Drug Delivery
WO2020245706A1 (en) 2019-06-06 2020-12-10 3M Innovative Properties Company N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
EP3983408A1 (en) * 2019-06-12 2022-04-20 3M Innovative Properties Company Phenethyl substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
EP3993834A1 (en) 2019-07-05 2022-05-11 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2021116420A1 (en) 2019-12-13 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
IL293926A (en) 2019-12-17 2022-08-01 Pfizer Antibodies unique to d47, pd-l1 and their uses
WO2021168318A1 (en) 2020-02-21 2021-08-26 International Aids Vaccine Initiative Inc. Vaccine compositions for preventing coronavirus disease
US20230165723A1 (en) 2020-04-30 2023-06-01 Kindeva Drug Delivery L.P. Adhesive article and method of making same
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
AU2021308586A1 (en) 2020-07-17 2023-03-02 Pfizer Inc. Therapeutic antibodies and their uses
CN116056765A (zh) 2020-08-07 2023-05-02 坦伯公司 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
FR3113287B1 (fr) 2020-08-07 2023-06-23 Phv Pharma Procédé industriel de synthèse de l’imiquimod à partir de la quinolèine-2,4-diol applicable à son utilisation pharmaceutique
CA3193244A1 (en) 2020-09-22 2022-03-31 Geoffrey Martin Lynn Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
WO2022086853A1 (en) 2020-10-19 2022-04-28 Avidea Technologies, Inc. Star polymer drug conjugates
US20230416244A1 (en) * 2020-12-09 2023-12-28 Wellstat Therapeutics Corporation Imidazoquinoline compound having anti-inflammatory, antifugal, antiparasitic, and anticancer activity
KR20230147135A (ko) 2021-02-16 2023-10-20 백시테크 노쓰 아메리카, 인크. 친양쪽성 펩티드에 기초한 자기-어셈블리 나노입자
ES2940736B2 (es) 2021-11-09 2023-09-19 Ntd Labs S L U Uso combinado de imiquimod y de un hidrolizado de caseina para el tratamiento de condilomas
WO2024092028A2 (en) 2022-10-25 2024-05-02 Vaccitech North America, Inc. Combination treatment regimes for treating cancer
WO2024092030A1 (en) 2022-10-25 2024-05-02 Vaccitech North America, Inc. Self-assembling nanoparticles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700674A (en) * 1969-04-30 1972-10-24 American Cyanamid Co 4-alkylamino-3-nitroquinolines
US4013665A (en) * 1973-10-01 1977-03-22 Bristol-Myers Company Antiviral, substituted 1,3-dimethyl-1h-pyrazolo(3,4b)quinolines
US4052393A (en) * 1975-11-03 1977-10-04 E. R. Squibb & Sons, Inc. 4-Substituted derivatives of pyrazolo [1,5-a]-quinoxaline-3-carboxylic acids and esters
US4191767A (en) * 1977-01-07 1980-03-04 Westwood Pharmaceuticals, Inc. Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines
US4197403A (en) * 1977-01-07 1980-04-08 Westwood Pharmaceuticals Inc. 4-Aminosubstituted imidazo(1,2-A)quinoxalines
GR78412B (pt) * 1981-12-30 1984-09-27 Ciba Geigy Ag
DE3364438D1 (en) * 1982-10-18 1986-08-14 Pfizer Triazoloquinoxalines as antidepressants and antifatigue agents
EP0187705A3 (en) * 1985-01-08 1988-05-11 Norwich Eaton Pharmaceuticals, Inc. Imidazo(4,5-f)quinolines useful as immunomodulating agents

Also Published As

Publication number Publication date
IL73534A (en) 1990-12-23
MX9203474A (es) 1992-07-01
CZ390491A3 (en) 1993-03-17
BR1100396A (pt) 1999-08-31
US4689338A (en) 1987-08-25

Similar Documents

Publication Publication Date Title
SK390491A3 (en) 1H-IMIDAZO/4,5-C/QUINOLIN-4-AMINE DERIVATIVES AND ANTIVIRALì (54) PHARMACEUTICAL COMPOSITIONS BASED THEREUPON
EP0145340B1 (en) 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines
JP3571342B2 (ja) 縮合シクロアルキルイミダゾピリジン
US4698348A (en) 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents
US5627281A (en) Intermediate compounds of fused cycloalkylimidazopyridines
EP0603251B1 (en) 1-substituted 1h-imidazo(4,5-c)quinolin-4-amines; intermediate and pharmaceutical compositions
EP0389302B1 (en) Olefinic 1H-imidazo [4,5-c]quinolin-4-amines
US5266575A (en) 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
EP0708772B1 (en) IMIDAZO [4,5-c]PYRIDIN-4-AMINES
PT99062A (pt) Processo para a preparacao de derivados de xantina
NZ232602A (en) Imidazo quinoline derivatives, preparation and pharmaceutical compositions thereof
US5916898A (en) Phenanthroline derivatives
KR20060092220A (ko) 유도성 ｎｏ-신타아제 저해제로서의 이미다조피리딘 유도체
US4798832A (en) Pyrido[1,2-a]pyrimidine compounds, corresponding intermediates and use as SRS-A antagonists